EGFR and lung adenocarcinoma: aimed to evaluate the applicability of quantitative assessment of EGFR driver mutations in plasma in NSCLC patients with EGFR mutations treated with EGFR-TKIs as a tool to evaluate the therapeutic response to TKIs and monitor disease progression; of 136 cases with susceptible EGFR mutation-positive lung adenocarcinoma confirmed by tissue biopsy; Blood samples were taken before TKI treatment and during at least two TKI treatments/follow-up.